Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Long-Acting Cabotegravir in HIV-Uninfected Chinese Men
NCT03422172Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs): Injection Phase, Number of Participants With Maximum Toxicity Post-Baseline in Hematology Parameters-Injection Phase and 11 more. Started Apr 2018; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03422172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422172.